Cardiomyopathy is often found in patients with Duchenne and Becker muscular dystrophy, which are X linked muscle diseases caused by mutations in the dystrophin gene. Dystrophin defects present in many different ways and cases of mild Becker muscular dystrophy have been described in which cardiomyopathy was severe. Female carriers of Duchenne muscular dystrophy can develop symptomatic skeletal myopathy alone or combined with dilated cardiomyopathy.
They can also develop dilated cardiomyopathy alone. X linked dilated cardiomyopathy has been found in association with dystrophin defects. The relation between the molecular defects and the cardiac phenotypes has not yet been established. New mutations in the dystrophin gene are common and such mutations cause one third of the cases with Duchenne and Becker muscular dystrophy. This means that sporadic cases of cardiomyopathy caused by dystrophin defects are likely. This paper reports such a case in a boy of 14 who died of dilated cardiomyopathy. Before the cardiac investigation, which was performed one month before he died, he had not complained of muscular weakness. He had minor signs of limb girdle myopathy and slightly increased concentrations of serum creatine kinase. He was found to have an unusual deletion in the dystrophin gene.
(Br Heart 7 1994; 72:344-348) Duchenne and Becker muscular dystrophy Duchenne muscular dystrophy is a X linked disease with onset in early childhood that causes severe muscle wasting and death before 25 <3 3 ,ukat/l)). Electromyography of the tibialis anterior, rectus femoris, and biceps brachii muscles was normal, whereas a biopsy specimen of skeletal muscle showed mild myopathic changes ( fig 1B) .
He was treated with digoxin, frusemide, and metoprolol. A cardiac transplantation was planned but the patient died one month later of congestive heart failure. A post-mortem examination was not performed.
The new knowledge of dystrophin prompted us to re-examine the muscle specimen obtained in 1987. Immunohistochemical analysis of dystrophin was performed on cryostat sections with monoclonal anti-dystrophin antibodies (DYS 1, DYS 2, and DYS 3, Novocastra Laboratories, UK). The DYS 1 antibody recognises an epitope between amino acids 1181 and 1388 (exons 26 to 30 approximately), the DYS 2 antibody reacts with the last 17 amino acids of the carboxy terminal of dystrophin, and the DYS 3 antibody detects sequences between amino acids 308 and 351, spanning the junction of exons 9 and 10.6 The immunoreactive material was visualised by the avidin-biotin complex (ABC)-peroxidase method with diaminobenzidine as chromogen. We performed Western blot analysis using the DYS 1 monoclonal antibody.303' For molecular genetic analysis DNA was extracted from muscle tissue (the patient) or blood (the mother and brother). We used multiplex polymerase reaction (PCR) analysis to detect the presence or absence of 18 different deletion-prone regions of the dystrophin gene.'2 33 We used three different primer pairs to analyse dinucleotide repeats in the DMD gene region. Immunohistochemical staining showed normal or slightly reduced immunoreactivity with the antibodies DYS 1 and DYS 2 and no immunoreactivity with antibody DYS 3 ( fig  2) . The PCR reaction did not amplify exons 6, 8, 12, and 13. The other 14 investigated segments of the dystrophin gene were amplified in a normal way, indicating a deletion from exon 6 to exon 13 that did not involve exon 4 and exon 17 ( fig 2) . Western blot analysis with the antibody DYS 1 showed a dystrophin protein of reduced size (fig 3) . These results show that a deletion in the dystrophin gene of the patient had shortened the dystrophin protein by removing a segment near the amino terminal region. The analysis of dinucleotide repeats showed that the patient and his healthy brother had received different haplotypes from their mother in the .... group.bmj.com on June 27, 2017 -Published by http://heart.bmj.com/ Downloaded from Dilated cardiomyopathy and the dystrophin gene: an illustrated review dystrophin gene. Therefore we could not unequivocally determine whether she is a carrier of the mutation.
Comments
Our patient had slight skeletal muscle involvement as judged by the small increase in s-CK and the minor muscle weakness; however, cardiac failure caused by dilated cardiomyopathy was severe. In this respect our case shows many features in common with patients in the recently described pedigrees with X linked dilated cardiomyopathy associated with dystrophin defects25 26 caused by different mutations. Theoretically the deletion in our patient did not cause a shift in the reading frame; this accords with the presence of a truncated protein on the Western blot. Exons 9 and 10 are only rarely involved in deletions without a frame shift.693735 This part of dystrophin may be a hinge region joining the amino terminal domain to the central rod domain, and may thus be of great importance to the conformation of dystrophin.39 This region may be more important in cardiac muscle than in skeletal muscle because our patient had severe cardiac disease and mild skeletal myopathy. Or perhaps the amount of dystrophin was more severely reduced in the myocardium than in skeletal muscle. We did not have the opportunity to investigate dystrophin in the myocardium. The amount of dystrophin is important to the clinical expression. Beggs et al described a 7 year old boy with skeletal myopathy and an in frame deletion of exons 6-13, but unlike our case this patient had very little dystrophin in skeletal muscle. 9 Though we could not unequivocally determine whether the mother of our patient is a carrier of the mutation, this case emphasises the importance of investigating the gene and gene expression of dystrophin not only in cases of muscular dystrophy and X linked dilated cardiomyopathy but also in sporadic cases of dilated cardiomyopathy, especially in young individuals with raised s-CK, because the results may have important implications for genetic counselling.
